

RESEARCH

Open Access

HTLV-1 bZIP factor supports proliferation of adult T cell leukemia cells through suppression of C/EBP α signaling

Tiejun Zhao^{1,2*}, Aaron Coutts^{2,4}, Lingling Xu¹, Juntao Yu¹, Koichi Ohshima³ and Masao Matsuoka^{2*}

Abstract

Background: Human T-cell leukemia virus type 1 (HTLV-1) is an oncogenic retrovirus etiologically associated with adult T-cell leukemia (ATL). The HTLV-1 bZIP factor (HBZ), which is encoded by minus strand of provirus, is expressed in all ATL cases and supports the proliferation of ATL cells. However, the precise mechanism of growth promoting activity of HBZ is poorly understood.

Results: In this study, we showed that HBZ suppressed C/EBP α signaling activation induced by either Tax or C/EBP α . As mechanisms of HBZ-mediated C/EBP α inhibition, we found that HBZ physically interacted with C/EBP α and diminished its DNA binding capacity. Luciferase and immunoprecipitation assays revealed that HBZ repressed C/EBP α activation in a Smad3-dependent manner. In addition, C/EBP α was overexpressed in HTLV-1 infected cell lines and fresh ATL cases. HBZ was able to induce C/EBP α transcription by enhancing its promoter activity. Finally, HBZ selectively modulated the expression of C/EBP α target genes, leading to the impairment of C/EBP α -mediated cell growth suppression.

Conclusion: HBZ, by suppressing C/EBP α signaling, supports the proliferation of HTLV-1 infected cells, which is thought to be critical for oncogenesis.

Keywords: HTLV-1, HBZ, C/EBP α

Background

Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia (ATL) [1,2]. HTLV-1 encodes several regulatory (*tax* and *rex*) and accessory (*p12*, *p13* and *p30*) genes in the pX region located between the *env* and 3' long terminal repeat (LTR) [3]. Among the viral genes, Tax is thought to play a central role in the pathogenesis of HTLV-1 [4]. Yet the expression of Tax cannot be detected in ~60% of fresh ATL cases due to epigenetic modifications or deletion of the 5'LTR [5]. In contrast, the *HTLV-1 bZIP factor* (HBZ), which is encoded by the minus strand of the HTLV-1 genome, is expressed in all ATL cases and supports the proliferation of HTLV-1 infected cells [6-8].

HTLV-2, a type of retrovirus which is similar with HTLV-1, encodes an antisense protein (APH-2) using the minus strand of its genome. However, APH-2 does not seem to promote cell proliferation [9,10]. HBZ was reported to repress Tax-mediated transactivation of viral transcription from the HTLV-1 5'LTR [11]. Moreover, HBZ dysregulated multiple cellular signalings including the classical pathway of NF- κ B, TGF- β , AP-1, and the Wnt pathways, which is likely to contribute to viral persistence and clonal expansion of infected cells [12-15].

The CCAAT/enhancer binding protein (C/EBP) family of proteins represents a critical group of bZIP transcription factors that are key to the regulation of cell proliferation, development, and immune responses [16,17]. Dysregulated C/EBP signaling is intimately associated with tumorigenesis and viral diseases [18]. Furthermore, the ability of C/EBPs to direct cellular fate is thought to depend on the presence of specific collaborating transcription factors, and allows C/EBPs to act as both tumor suppressors and tumor promoters under different conditions [17]. C/EBP α , the

* Correspondence: tjzhao@zjnu.cn; mmatsuoka@virus.kyoto-u.ac.jp

¹College of Chemistry and Life Sciences, Zhejiang Normal University, 688 Yingbin Road, Jinhua, Zhejiang 321004, China

²Laboratory of Virus Control, Institute for Virus Research, Kyoto University, 53 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

Full list of author information is available at the end of the article

founding member of this family, has been demonstrated to be important for differentiation of several cell types [19]. On the other hand, C/EBP α emerged as an important negative regulator of cell proliferation [20]. Thus, most tumors have evolved distinct strategies to attenuate C/EBP α function [17,21]. Known mechanisms of C/EBP α suppression in cancer cells include (1) transcriptional downregulation of *CEBPA* expression; (2) point mutations and deletions in C/EBP α ; and (3) inhibition of C/EBP α transcriptional activation through protein-protein interaction. However, normal C/EBP α is overexpressed in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), and inhibits apoptosis by upregulating bcl-2 and FLIP expression [22,23]. It suggested that C/EBP α may exhibit oncogenic as well as tumour suppressor properties in human leukaemogenesis.


In ATL, Tax has been shown to bind to CCAAT binding proteins such as nuclear factor YB subunit (NF-YB) and C/EBP β [24]. Through its association with NF-YB, Tax activates the major histocompatibility complex class II (MHC-II) promoter [24]. Additionally, C/EBP β was capable of inhibiting Tax-dependent transactivation of the HTLV-1 LTR, as well as efficiently decreasing Tax synthesis from an infectious HTLV-1 molecular clone [25]. On the other hand, expression of Tax increases binding of C/EBP β to and activates the IL-1 β promoter [26]. Interestingly, previously published microarray data showed that the *CEBPA* gene was overexpressed in adult T-cell leukemia cells [27,28]. It is thus likely that the dysregulated C/EBP signaling pathway may play a role in ATL.

Although regulation of C/EBP signaling by Tax has been reported, little is known about whether other viral proteins affect C/EBP signaling. In the present study, we found that HBZ suppressed C/EBP signaling by interacting with C/EBP α , resulting in the impairment of C/EBP α -mediated cell growth suppression. This might account for why HBZ supports the proliferation of HTLV-1 infected cells.

Results

HBZ suppresses C/EBP α signaling

To investigate the effect of HBZ on the C/EBP signaling pathway, Jurkat cells were cotransfected with expression vectors of C/EBP α and HBZ along with a C/EBP-responsive reporter: C/EBP-Luc. As shown in Figure 1A, C/EBP α enhanced the transcription of luciferase, while HBZ inhibited C/EBP α -mediated C/EBP signaling activation in a dose-dependent manner. It was reported that C/EBP transcription factors dysregulated transcription from long terminal repeat [25]. We therefore analyzed whether HBZ could modulate HTLV-1 promoter activity through C/EBP signaling. Consistent with previous reports, overexpression of C/EBP α inhibited Tax-mediated



HTLV-1 LTR activation [29]. Moreover, HBZ overcame the repression of HTLV-1 viral transcription by C/EBP α (Figure 1B). These results collectively indicate that HBZ impairs the function of C/EBP α .

HBZ interacts with C/EBP α

Accumulating evidences show that HBZ dysregulates signaling pathways in ATL by associating with multiple transcriptional factors [8,12-15,30,31]. To clarify the molecular mechanism by which HBZ suppresses the C/EBP α transcriptional response, we investigated whether HBZ can physically interact with C/EBP α . FLAG-tagged C/EBP α and mycHis-tagged HBZ were cotransfected into 293T cells, and an immunoprecipitation assay was performed. Figure 2A illustrates that HBZ interacted with C/EBP α . The HBZ-C/EBP α association was further analyzed by confocal microscopy. Cotransfected cells showed nuclear spots representing co-localization of HBZ and C/EBP α protein (Figure 2B). To investigate whether HBZ influences the ability of C/EBP α to bind its DNA target, we performed a ChIP assay in 293T cells that were cotransfected with C/EBP-Luc reporter together with expression vectors of HBZ and C/EBP α .

The ChIP assay detected the association of C/EBP α with its responsive elements, while HBZ dramatically decreased C/EBP α 's DNA binding capability (Figure 2C). Previous reports showed that HBZ decreased the expression level of its associated proteins [12,13]. Therefore, we analyzed whether HBZ could also affect the expression of C/EBP α . As shown in Figure 2D, HBZ did not induce C/EBP α protein degradation even at high doses. In addition, C/EBP α did not influence HBZ expression (Additional file 1: Figure S1). These observations suggest that HBZ represses C/EBP α -induced transcription through physical association between HBZ and C/EBP α .

HBZ depends on Smad3 to inhibit C/EBP α -mediated transcription

Several reports have indicated that Smad3 interacted with C/EBP and repressed C/EBP transactivation function [32,33]. Moreover, HBZ could enhance the Smad3-




Figure 2 HBZ interacted with C/EBP α protein. **(A)** HBZ interacted with C/EBP α . 293T cells were cotransfected with mycHis-HBZ together with FLAG-C/EBP α . After 48 hours, cell lysates were subjected to immunoprecipitation using anti-c-Myc followed by immunoblotting using anti-FLAG. **(B)** HBZ co-localized with C/EBP α . HeLa cells were transfected with mycHis-HBZ and FLAG-C/EBP α . HBZ was detected using anti-MYC Cy3 antibody (ii). C/EBP α was detected using anti-Flag-biotin and secondary Streptavidin-Alexa 488 antibody (i). The overlay of HBZ and C/EBP α is shown (iii). **(C)** HBZ decreased C/EBP α 's DNA binding capability. After transfection with mycHis-HBZ, FLAG-C/EBP α , and pC/EBP α -Luc for 48 hours, 293T cells were chromatin immunoprecipitated by anti-FLAG antibody. The precipitated DNAs and 1% of the input cell lysates were amplified by the pC/EBP-Luc specific primers. Expression of HBZ and C/EBP α was detected by Western blot (bottom panel). **(D)** HBZ could not repress the level of C/EBP α . 293T cells were transfected with expression vector of C/EBP α and various amounts of mycHis-HBZ. After 48 hours, the cell lysates were subjected to immunoblotting.

mediated TGF- β pathway [14]. To determine whether Smad3 is required for HBZ to suppress C/EBP α , we analyzed the effect of SIS3, an inhibitor of Smad3, on the ability of HBZ to inhibit C/EBP α transcriptional activity. Figure 3A demonstrates that SIS3 impaired the ability of HBZ to suppress transcriptional activity through C/EBP-responsive elements. In addition, when Smad3 expression was inhibited by siRNA, the HBZ-mediated suppression of C/EBP α activity was partially restored, indicating that Smad3 functions to suppress

C/EBP α signaling along with HBZ (Figure 3B). We next explored whether HBZ, C/EBP α , and Smad3 could form a ternary complex. Vectors expressing mycHis-HBZ, FLAG-Smad3, and HA-C/EBP α were cotransfected into 293T cells, and a serial immunoprecipitation assay was performed. As shown in Figure 3C, and Additional file 2: Figure S2, we detected a specific ternary complex only when the three components were coexpressed. These results together suggest that HBZ inhibits C/EBP α signaling by forming complexes of HBZ-Smad3-C/EBP α .




Figure 3 Smad3 was involved in the suppression of C/EBP α signaling by HBZ. (A) SIS3 overcame HBZ-induced repression of C/EBP α . Six hours after SIS3 (5 μ M) treatment, Jurkat cells were cotransfected with pC/EBP-Luc (0.5 μ g), pRL-TK (10 ng), pME18Sneo-HBZ (2 μ g), and pCMV-Tag-C/EBP α (0.5 μ g). Luciferase activity was measured 48 hours after transfection. (B) Reducing SMAD3 expression by siRNA recovered HBZ mediated suppression of C/EBP α . HepG2 cells were transfected with expression vectors together with Smad3 siRNA or control siRNA. SMAD3 mRNA expression was analyzed by RT-PCR. Luciferase activity was measured 48 hours after transfection. (C) HBZ, Smad3, and C/EBP α could form a ternary complex. mycHis-HBZ, FLAG-Smad3, and HA-C/EBP α were cotransfected into 293T cells. Ternary complexes were detected by sequential immunoprecipitation with anti-FLAG agarose affinity gel and anti-HA antibody, followed by immunoblotting with the His antibody.

Domains of HBZ responsible for suppression of C/EBPα

Next, we evaluated the region of HBZ responsible for the inhibition of C/EBP signaling. To this end, we tested the HBZ deletion mutants shown in Figure 4A. Figure 4B demonstrated that wild-type HBZ down-regulated C/EBPα-mediated transcriptional responses. Compared with other mutants, only the HBZ ΔCD mutant exhibited suppressive activity. We mapped the region of HBZ interacting with C/EBPα in detail. As shown in Figure 4C, full-length HBZ and three of its deletion mutants (HBZ-ΔAD,

HBZ-ΔbZIP, and HBZ-ΔCD) associated with C/EBPα, while HBZ-AD and HBZ-bZIP have no binding capability. These results collectively indicate that both the AD and bZIP domains in HBZ were necessary for suppression of the C/EBPα pathway. To define which part of C/EBPα binds HBZ, we performed a co-immunoprecipitation assay with C/EBPα mutants (Figure 4D). The C/EBPα-ΔbZIP mutant, which did not contain the bZIP domain, was incapable of interacting with HBZ. However, the mutant containing only the bZIP domain of C/EBPα still




Figure 4 Domains of HBZ responsible for the suppression of C/EBPα signaling. (A) Schematic diagram of HBZ and its mutants used in this study. Characteristic domains of HBZ are indicated as follows: activation domain (AD), central domain (CD), and basic leucine zipper domain (bZIP). (B) Analysis of HBZ deletion mutants for their effect on C/EBPα-mediated signaling. Jurkat cells were cotransfected with pC/EBP-Luc, phRL-TK, pCMV-Tag-C/EBPα and pME18Sneo-HBZ mutants. After 48 hours, the cells were harvested and analyzed for Luciferase activity. * $P < 0.05$; ** $P < 0.01$. (C) Determination of the region of HBZ responsible for the interaction with C/EBPα. 293T cells were transfected with the indicated mycHis-HBZ mutants together with the FLAG-C/EBPα. Cell lysates were subjected to immunoprecipitation using anti-c-Myc followed by immunoblotting using anti-FLAG. (D) The schema of C/EBPα deletion mutants is shown. The locations of the AD domain and the bZIP domain are indicated. (E) Mapping the region of the C/EBPα protein necessary for interaction with HBZ. 293T cells were transfected with mycHis-HBZ and full-length or mutant FLAG-C/EBPα. At 48 hours after transfection, total cell lysates were subjected to IP using anti-FLAG followed by IB using anti-His.

interacted efficiently with HBZ protein. Thus, the interaction with HBZ is mediated by the bZIP segment of C/EBP α (Figure 4E).

C/EBP α is overexpressed in ATL

We next checked the expression level of *CEBPA* mRNA and protein in ATL. Three healthy donors and six ATL patients with different age and disease status were included in this study. CD4 positive cells were isolated from PBMCs of the clinical samples, and real-time PCR was performed to analyze the expression of *CEBPA* mRNA. Compared with normal T cells, all ATL patients constitutively expressed *CEBPA* transcript. Noticeably, the three youngest patients who suffered from acute ATL expressed higher levels of *CEBPA* compared with the other three patients (Figure 5A). Immunohistochemical analysis of lymph nodes of ATL patients showed that lymphoma cells indeed expressed C/EBP α (Figure 5B). Quantitative analyses revealed increased expression of

CEBPA in HTLV-1-infected cell lines compared with noninfected ones (Figure 5C). Moreover, high levels of C/EBP α protein were detected in ATL cell lines (Figure 5D).

C/EBP α expression is induced by HBZ

It is well established that HBZ is the only viral gene that remains intact and is constitutively expressed in all ATL cases [34]. Considering that the level of C/EBP α is elevated in ATL and HTLV-1 associated cell lines, we evaluated whether HBZ controlled the excess expression of C/EBP α . As shown in Figure 6A, the *CEBPA* gene was upregulated in Kit 225 cells, which stably express HBZ. To investigate HBZ-mediated enhancement of *CEBPA* expression *in vivo*, we studied the level of *CEBPA* in splenic CD4⁺ T cells from HBZ transgenic mice. Consistently, expression of *CEBPA* was upregulated in HBZ transgenic mice as observed *in vitro* (Figure 6B). We further analyzed the mechanism by which HBZ induced




Figure 5 C/EBP α was overexpressed in ATL. (A) High expression of *CEBPA* in ATL. CD4 positive cells were isolated from PBMCs of healthy donors and ATL patients, and real-time PCR was performed to analyze the expression of *CEBPA* mRNA. H indicates healthy donors, P indicates ATL patients. (B) Determination of C/EBP α in ATL patient by immunohistochemical analysis. Lymph nodes of an ATL patient was fixed, and C/EBP α was subjected to immunostaining with anti-C/EBP α antibody. (C) *CEBPA* is overexpressed in HTLV-1 associated cell lines. Quantitative analysis of *CEBPA* mRNA in HTLV-1-negative (open bars) and HTLV-1-positive cell lines (black bars) by real-time PCR. (D) Overexpression of C/EBP α protein in HTLV-1 cell lines. Cell lysates of HTLV-1-negative and HTLV-1-positive cell lines was subjected to immunoblotting with anti-C/EBP α .




Figure 6 HBZ induced *C/EBPα* expression. Total RNA was extracted from control or HBZ-expressing Kit 225 (A) and CD4⁺ cells of HBZ transgenic mice (B). Real-time PCR was performed to analyze the expression of *CEBPA* mRNA. (C) HBZ activated transcription of the *CEBPA* promoter. 293T cells were transfected with the *C/EBPα* reporter plasmid with or without the HBZ-expressing plasmid. Luciferase activity was measured 48 hours after transfection. (D) HBZ binds to the *C/EBPα* promoter. After transfection with mycHis-HBZ and *C/EBPα* reporter vector for 48 hours, 293T cells were chromatin immunoprecipitated by anti-c-Myc antibody. The precipitated DNAs and 1% of the input cell lysates were amplified by the specific primers for *CEBPA* promoter.

C/EBPα expression. The 2-kb fragment of the *CEBPA* promoter region was cloned into the pGL4.10 reporter vector and a luciferase assay was performed. As shown in Figure 6C, HBZ enhanced transcription from the *CEBPA* promoter. In addition, a chromatin immunoprecipitation assay detected HBZ bound to the *CEBPA* promoter (Figure 6D). These results collectively indicate that the enhanced induction of *CEBPA* expression by HBZ can be attributed, at least in part, to the association of HBZ with the *CEBPA* promoter.

HBZ overcomes *C/EBPα*-mediated suppression of T-cell proliferation

Previous studies have shown that *C/EBPα* inhibits cell proliferation and induces cell cycle arrest [17]. We confirmed that the growth of mouse CD4⁺ T cells was inhibited by enforced expression of *C/EBPα* (Figure 7A). To address whether HBZ could affect cell proliferation by suppressing *C/EBPα* signaling, we overexpressed HBZ and *C/EBPα* in primary mouse CD4⁺ T cells. Figure 7B demonstrated that *C/EBPα* repressed T cell




Figure 7 HBZ overcame the C/EBPα-mediated growth suppression. **(A)** Mouse CD4⁺CD25⁻ T cells were transduced with pGCDNsaml/GFP vector encoding C/EBPα, or with empty vector. At three days after infection, cell proliferation was analyzed by flow cytometry. **(B)** Mouse CD4⁺CD25⁻ T cells were transduced with pGCDNsaml/NGFR vector encoding HBZ together with pGCDNsaml/GFP-C/EBPα. Cells were stained with specific antibody at the time points indicated, and cell growth was detected by flow cytometry. Representative data from three independent experiments are shown. **(C)** HBZ modulated the expression of selected C/EBPα target genes. Total RNA was extracted from samples from the experiment of Figure 7B. The level of *MYC*, *FLIP*, *IFN-γ*, *BCL2*, *DHFR*, *E2F1*, *PER2*, *CDKN1A*, *IL6*, *IL4*, *PCNA*, *CDK2*, *β-actin*, *CEBPA*, and *HBZ* mRNA were analyzed by semiquantitative RT-PCR. **(D)** Transcriptional changes of selected C/EBPα target genes in CD4⁺ thymocytes from HBZ transgenic mice. After stimulating the cells with PMA plus ionomycin, the levels of *MYC*, *FLIP*, *E2F1*, *PER2*, *IL6*, *PCNA*, *β-actin*, *CEBPA*, and *HBZ* mRNA were analyzed by semiquantitative RT-PCR.

proliferation, whereas HBZ-expressing cells proliferated regardless of C/EBP α . We next studied the effect of HBZ on transcription of C/EBP α -specific target genes using mouse naïve T cells expressing HBZ. Previous reports showed that C/EBP α suppressed cell proliferation by inhibiting the expression of *E2F1*, *DHFR*, and *PCNA*. When co-expressed with C/EBP α , HBZ enhanced *E2F1*, *DHFR*, *PCNA*, *FLIP*, *BCL2*, *IL6*, and suppressed *IL4* and *IFN- γ* (Figure 7C). This indicated that HBZ overcame the suppressive effect of C/EBP α on its target genes, leading to the cell growth. To investigate HBZ-mediated suppression of C/EBP α signaling *in vivo*, we studied the expression of C/EBP α -specific target genes in thymus CD4⁺ cells from HBZ transgenic mice. As shown in Figure 7D, expression of HBZ was associated with enhanced transcription of *CEBPA*, *E2F1*, *PCNA*, and *IL6* genes and suppression of *FLIP* gene; such effects were consistent with the observation in HBZ transfected naïve T cells.

These results together indicate that HBZ supports the proliferation of T cells through dysregulation of C/EBP α signaling as well as selective modulation of transcription of C/EBP α target genes.

Discussion

After transmission, HTLV-1 increases its viral copy number by clonal proliferation of infected cells and results in the onset of ATL [5,35]. In this strategy, Tax was thought to play a critical role in increasing the number of HTLV-1-infected cells by promoting proliferation and inhibiting apoptosis [36,37]. However, because Tax is the major target of cytotoxic T lymphocytes (CTLs), it is frequently inactivated by genetic and epigenetic modifications [5,38]. Therefore, HTLV-1 has evolved mechanisms to maintain cell survival in a Tax-independent manner. We have reported that HBZ, which is consistently expressed in ATL, promotes the proliferation of T-lymphocytes *in vitro*, and increases splenic CD4⁺ T-cells in HBZ transgenic mice, indicating a role for HBZ, like tax, in the proliferation of HTLV-1 infected cells [7,31]. So far, the mechanism by which HBZ promotes proliferation of leukemic cells has not been well elucidated. Accumulating evidence shows that C/EBP α possesses the ability to arrest cell proliferation through upregulation of CDKN1A (p21) as well as direct inhibition of E2F [39]. We firstly present evidence that C/EBP α is highly expressed in ATL. However, C/EBP α 's growth-suppression function is impaired by HBZ, resulting in the proliferation of ATL cells despite C/EBP α expression. It is thus likely that HBZ may support the proliferation of HTLV-1 infected cells, whereas other mechanisms, which include dysregulation of C/EBP α signaling and selectively modulate C/EBP α target gene expression. In support of our hypothesis, we showed in this study that HBZ enhanced the expression of *E2F1*,

PCNA, and *DHFR* genes in C/EBP α -expressing cells and did not interfere with *MYC*, *CDKN1A*, and *CDK2* expression, contrary to the effect of C/EBP α alone [7].

Apart from the growth suppression function, C/EBP family proteins have oncogenic properties [17,21]. Consistent with our findings, recent studies reported that overexpression of C/EBP α occurs in cancer, such as B precursor acute lymphoblastic leukemia (ALL) and a subset of human hepatocellular carcinomas (HCCs) [22,40]. Importantly, C/EBP α induces *BCL2* and *FLIP* gene expression in cooperation with NF- κ B p50, allowing cancer cells to escape apoptosis [23]. We showed here that C/EBP α was overexpressed in ATL, whereas its growth-suppressive function was impaired by the effect of HBZ. In this regard, it is meaningful to raise the question: why do ATL cells need high levels of C/EBP α ? It has been reported that HBZ suppressed apoptosis of HTLV-1 infected cells, while the underlying mechanism is still unknown. As shown in Figure 7C, HBZ selectively suppressed the level of C/EBP α target genes which related with cell growth, but did not inhibit the C/EBP α -induced expression of anti-apoptotic genes including *BCL2* and *FLIP*, suggesting that HBZ may fulfill its anti-apoptotic function through dysregulation of C/EBP α signaling.

Immunodeficiency in ATL patients is pronounced, and results in frequent opportunistic infections by various pathogens [41,42]. As a mechanism of this immunodeficiency, HBZ has been shown to inhibit CD4 T-cell responses, resulting in impaired host immunity *in vivo* [31,43]. Further study demonstrated that HBZ transgenic mice, which expressed excess amount of C/EBP α , were vulnerable to opportunistic pathogens [31]. It was reported that a population of PD-1⁺ memory phenotype CD4⁺ T cell underlies the global depression of the T cell immune response, and such features are attributable to an unusual expression of C/EBP α [44]. Like C/EBP α , C/EBP β acts as a master regulator of the tolerogenic and immunosuppressive environment induced by cancer [45]. Thus, our results now open the possibility that HBZ may induce the expression of C/EBP α , leading to immunodeficiency in ATL, and perhaps to oncogenesis. Further studies on C/EBP signaling in ATL are necessary to clarify its roles.

Many viruses have developed distinct strategies to modulate C/EBP α signaling using their own viral proteins. Examples include hepatitis B virus pX; Epstein-Barr virus BZLF; as well as human immunodeficiency virus TAT and Vpr [46-48]. Like HBZ, the HBV pX and EBV BZLF protein prevent C/EBP-mediated activation by interacting directly with C/EBP family members. Similar upregulation of C/EBP expression has been reported for other viruses, including hepatitis C virus, Kaposi's sarcoma-associated herpes virus, and human

immunodeficiency virus [49-51]. These findings show that dysregulation of C/EBP pathways are common among different viruses, suggesting that these activities are critical for viral persistence and oncogenesis.

Accumulating evidences show that HBZ's oncogenic function can be attributed, at least in part, to its selective regulation of multiple signaling pathways in ATL [13-15,30,31]. For example, HBZ inactivates classical NF- κ B signaling without inhibiting the alternative pathway, helping cells to evade senescence and supporting cell proliferation [13,52]. Similarly, the negative effects of transcription factors which include ATF3, Wnt5a, and Smad3, were impeded by HBZ, leaving these factors to elude host immune attack and promote cell proliferation [14,15,30]. In this study, we found that HBZ selectively impaired the growth suppression function of C/EBP α , rendering the immunosuppressive and anti-apoptotic effect of C/EBP α predominant. HTLV-1 might escape from host immune surveillance and induce cell proliferation by thus selectively modulating signaling pathways, promoting viral reproduction, and also ATL.

It has been reported that HBZ is not able to form stable homodimers and is therefore dependent on heterodimerization with other proteins to control gene transcription [53]. Thus, the function of HBZ depends, at least in part, on its binding partner. Indeed, HBZ selectively suppressed the classical NF- κ B pathway through inhibiting DNA binding of p65 as well as PDLIM2-dependent p65 degradation. The specificity of PDLIM2 E3 ligase in targeting p65 protein, but not p52 of the alternative pathway, may possibly explain why HBZ selectively inhibits the classical pathway of NF- κ B [13]. Similarly, we showed in this study that HBZ inhibited C/EBP α signaling via recruitment of Smad3. Because the association with Smad proteins is crucial for C/EBP α in determining its target genes as well as transcriptional outcome, it is likely that the function of HBZ-Smad3-C/EBP α complexes depends on the capacity of HBZ to recruit Smad3-C/EBP α heterodimers onto the DNA target [32,54].

Conclusion

We showed that HBZ impaired the growth suppression function of C/EBP signaling by physically interacting with C/EBP α . HTLV-1 may take advantage of this mechanism to allow the infected cells to proliferate *in vivo*.

Methods

Cell culture, mice, and clinical samples

293T, HeLa, and HepG2 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics. HTLV-1 immortalized cell lines (MT-4), ATL cell lines (MT-1, ATL-2, ATL-43T, ED, and TL-Om1), and T-cell lines not infected with HTLV-1 (Jurkat) were cultured in

RPMI 1640 supplemented with 10% FBS and antibiotics. Kit 225 cells stably expressing HBZ were maintained as described previously [7]. C57BL/6 mice were purchased from CLEA Japan (Tokyo, Japan). Transgenic HBZ mice expressing HBZ specifically in CD4⁺ cells have been described [55]. Peripheral blood mononuclear cells (PBMCs) were isolated from ATL patients (n = 6), and healthy volunteers (n = 3). Details of clinical samples are shown in Additional file 3: Table S1. The study of clinical samples was conducted according to the principles expressed in the Declaration of Helsinki and approved by the Institutional Review Board of Kyoto University (844 and E-921). All patients provided written informed consent for the collection of samples and subsequent analysis.

Plasmids

The pC/EBP-Luc construct contains three tandem C/EBP binding sites and was purchased from Stratagene (Heidelberg, Germany). phRL-TK was purchased from Promega (Madison, WI). Reporter vector pLTR-Luc as well as expression plasmids for Tax, Smad3, HBZ, and HBZ deletion mutants were prepared as previously described [7,13,14]. Expression vectors for C/EBP α and its deletion mutants were generated by PCR.

Luciferase assay

Jurkat cells were plated on 6-well plates at 3.5×10^5 cells per well. After 24 hours, cells were transfected with the indicated luciferase plasmid DNA. Forty-eight hours after transfection, a luciferase reporter assay was performed as previously described [13]. For the C/EBP α reporter assay, the *CEBPA* gene promoter was cloned into the pGL4.1 vector. Luciferase values were normalized to renilla luciferase and expressed as the mean of a triplicate set of experiments \pm SD.

Immunoprecipitation and immunoblotting

293T cells were transfected with the indicated combinations of expression vectors by *TransIT-LT1* (Mirus, Madison, WI). Tagged proteins were immunoprecipitated by anti-c-Myc (clone 9E10, Sigma-Aldrich, St Louis, MO), anti-HA (12CA5, Roche, Mannheim, Germany) or anti-FLAG M2 (Sigma-Aldrich) antibodies, and analyzed by Western blot. Serial immunoprecipitation was performed as described previously [14]. Other antibodies used were as follows: anti-mouse immunoglobulin G (IgG), and anti-rabbit IgG were from GE Healthcare Life Sciences, and anti-C/EBP α from Santa Cruz Biotechnology (Santa Cruz, CA).

Immunofluorescence analysis

HeLa cells were transfected with expression vectors using *TransIT-LT1*. Forty-eight hours after transfection, HBZ protein was detected using anti-c-MYC Cy3 (clone 9E10, Sigma-Aldrich). C/EBP α was detected using anti-FLAG-

biotin (Sigma-Aldrich) and secondary Streptavidin-Alexa 488 antibody (Invitrogen, Carlsbad, CA). Fluorescence was observed with a confocal microscope system (Leica, Wetzlar, Germany) as described previously [14].

Chromatin immunoprecipitation assay

293T cells were transfected with the HBZ and C/EBP α expression vectors together with pC/EBP-Luc reporter vector. Forty-eight hours after transfection, chromatin immunoprecipitation (ChIP) assay was performed as previously described [14]. Precipitated DNA was amplified by PCR using primers specific for the pC/EBP-Luc plasmid. Sequences for the primer set were 5'-TCACTGCATTCTAGTTG TGG-3' and 5'-CCATCCTCTAGAGGATAGA-3'.

Semiquantitative RT-PCR and quantitative real-time PCR

Total RNA was isolated using Trizol Reagent (Invitrogen) according to the manufacturer's instructions. We reverse transcribed total RNA into single-stranded cDNA with SuperScript III reverse transcriptase (Invitrogen). For semiquantitative PCR, cDNA was amplified by increasing PCR cycles using forward (F) and reverse (R) primers specific to the target genes. In the real-time PCR experiment, cDNA product was quantified with Power SYBR Green PCR Master Mix and StepOnePlus Real Time PCR System (Life technologies). Endogenous β -actin mRNA was quantified to normalize the amount of cDNA load. The specific primers used can be found in Additional file 4: Table S2.

Immunohistochemical analyses

The tissue specimens were obtained from human lymph nodes filed at the Department of Pathology at Kurume University. Tissue samples were fixed in 10% formalin in phosphate buffer and then embedded in paraffin and analyzed by immunohistochemical methods to determine C/EBP α expression. Images were captured using a Provis AX80 microscope equipped with an OLYMPUS DP70 digital camera, and detected using a DP manager system (Olympus, Tokyo, Japan). The study of clinical samples was approved by the local research ethics committee of Kurume University.

Small interfering RNA (siRNA) transfection

siRNA targeted to human Smad3 was synthesized according to a previous report [56]. HepG2 cells were transfected with expression vectors and siRNA using *TransIT-LT1* according to the manufacturer's instructions. RT-PCR detected *SMAD3* 48 hours after transfection.

Retroviral constructs and transduction

pGCDNsami/NGFR-HBZ and pGCDNsami/GFP-C/EBP α retroviral constructs were generated by cloning HBZ and C/EBP α cDNA into the pGCDNsami/NGFR and

pGCDNsami/GFP vectors respectively. Transfection of Plat-E packaging cell line was performed as described [57]. Mouse splenocytes were enriched for CD25⁺CD4⁺ cells with a CD4 T lymphocyte enrichment set (BD Biosciences) with the addition of biotinylated anti-CD25 antibody (BD Biosciences), and activated by APCs in the presence of anti-CD3 antibody and human rIL-2 in 12-well plates. After 24 hours, activated T cells were transduced with viral supernatant and polybrene, and centrifuged at 3,000 rpm for 60 minutes. Cells were subsequently cultured in medium supplemented with rIL-2.

Flow cytometric analysis

Murine cells were washed with PBS containing 1% FBS. After centrifugation, cells were treated with APC-conjugated anti-human NGFR antibody (BD Biosciences) for 30 minutes. After being washed with PBS, the cells were analyzed with a flow cytometer (BD FACSCanto II, BD Biosciences).

Statistical analyses

Statistical analyses were performed using the unpaired Student *t* test.

Additional files

Additional file 1: Figure S1. C/EBP α did not influence HBZ expression. 293T cells were transfected with expression vector of HBZ and increasing amounts of C/EBP α . After 48 hours, the cell lysates were subjected to Western blot.

Additional file 2: Figure S2. HBZ, Smad3, and C/EBP α formed a ternary complex. mycHis-HBZ, FLAG-Smad3, and HA-C/EBP α were cotransfected into 293T cells. After 48 hours, cell lysates were subjected to immunoprecipitation using anti-c-Myc or anti-FLAG followed by immunoblotting using anti-FLAG, anti-His, and anti-HA antibody.

Additional file 3: Table S1. List of healthy donors and ATL patients. The information of six ATL patients and three healthy volunteers are listed.

Additional file 4: Table S2. List of primers for semi-quantitative RT-PCR and quantitative real-time PCR. We performed semi-quantitative RT-PCR and quantitative real-time PCR using the following primers.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

This study was designed by TZ, AC, and MM. Laboratory analysis was performed by TZ, AC, LX, and JY. Data analysis was performed by TZ, AC, LX, JY, and MM. Clinical samples and data were provided by KO. TZ, AC, and MM wrote the paper. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by a grant from National Natural Science Foundation of China to TZ (No.31200128); a Grant-in-aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan to MM; a grant from the Sciences Foundation of Zhejiang Normal University to TZ; and a grant from Technology Foundation for Selected Overseas Chinese Scholar to TZ.

Author details

¹College of Chemistry and Life Sciences, Zhejiang Normal University, 688 Yingbin Road, Jinhua, Zhejiang 321004, China. ²Laboratory of Virus Control, Institute for Virus Research, Kyoto University, 53 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. ³Department of Pathology, School of Medicine, Kurume University, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan. ⁴Present address: School of Medicine, The University of Queensland, Herston 4006, Australia.

Received: 27 July 2013 Accepted: 11 December 2013

Published: 21 December 2013

References

1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H: **Adult T-cell leukemia: clinical and hematologic features of 16 cases.** *Blood* 1977, **50**:481–492.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC: **Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.** *Proc Natl Acad Sci USA* 1980, **77**:7415–7419.
3. Journo C, Douceron E, Mahieux R: **HTLV gene regulation: because size matters, transcription is not enough.** *Future Microbiol* 2009, **4**:425–440.
4. Grassmann R, Aboud M, Jeang KT: **Molecular mechanisms of cellular transformation by HTLV-1 Tax.** *Oncogene* 2005, **24**:5976–5985.
5. Matsuoka M, Jeang KT: **Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation.** *Nat Rev Cancer* 2007, **7**:270–280.
6. Gaudray G, Gachon F, Basbous J, Biard-Piechaczyk M, Devaux C, Mesnard JM: **The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription.** *J Virol* 2002, **76**:12813–12822.
7. Satou Y, Yasunaga J, Yoshida M, Matsuoka M: **HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells.** *Proc Natl Acad Sci USA* 2006, **103**:720–725.
8. Zhao T, Matsuoka M: **HBZ and its roles in HTLV-1 oncogenesis.** *Front Microbiol* 2012, **3**:247.
9. Douceron E, Kaidarova Z, Miyazato P, Matsuoka M, Murphy EL, Mahieux R: **HTLV-2 APH-2 expression is correlated with proviral load but APH-2 does not promote lymphocytosis.** *J Infect Dis* 2012, **205**:82–86.
10. Halin M, Douceron E, Clerc I, Journo C, Ko NL, Landry S, Murphy EL, Gessain A, Lemasson I, Mesnard JM, et al: **Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription.** *Blood* 2009, **114**:2427–2438.
11. Lemasson I, Lewis MR, Polakowski N, Hivin P, Cavanagh MH, Thebault S, Barbeau B, Nyborg JK, Mesnard JM: **Human T-cell leukemia virus type 1 (HTLV-1) bZIP protein interacts with the cellular transcription factor CREB to inhibit HTLV-1 transcription.** *J Virol* 2007, **81**:1543–1553.
12. Matsumoto J, Ohshima T, Isono O, Shimotohno K: **HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein.** *Oncogene* 2005, **24**:1001–1010.
13. Zhao T, Yasunaga J, Satou Y, Nakao M, Takahashi M, Fujii M, Matsuoka M: **Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB.** *Blood* 2009, **113**:2755–2764.
14. Zhao T, Satou Y, Sugata K, Miyazato P, Green PL, Imamura T, Matsuoka M: **HTLV-1 bZIP factor enhances TGF-beta signaling through p300 coactivator.** *Blood* 2011, **118**:1865–1876.
15. Ma G, Yasunaga J, Fan J, Yanagawa S, Matsuoka M: **HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells.** *Oncogene* 2012, **32**:4222–4230.
16. Ramji DP, Foka P: **CCAAT/enhancer-binding proteins: structure, function and regulation.** *Biochem J* 2002, **365**:561–575.
17. Nerlov C: **The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control.** *Trends Cell Biol* 2007, **17**:318–324.
18. Tsukada J, Yoshida Y, Kominato Y, Auron PE: **The CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated system for gene regulation.** *Cytokine* 2011, **54**:6–19.
19. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG: **Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice.** *Proc Natl Acad Sci USA* 1997, **94**:569–574.
20. Halmos B, Huettner CS, Kocher O, Ferenczi K, Karp DD, Tenen DG: **Down-regulation and antiproliferative role of C/EBPalpha in lung cancer.** *Cancer Res* 2002, **62**:528–534.
21. Fuchs O: **Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias.** *Folia Biol (Praha)* 2007, **53**:97–108.
22. Chapiro E, Russell L, Radford-Weiss I, Bastard C, Lessard M, Struski S, Cave H, Fert-Ferrer S, Barin C, Maarek O, et al: **Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia.** *Blood* 2006, **108**:3560–3563.
23. Paz-Priel I, Ghosal AK, Kowalski J, Friedman AD: **C/EBPalpha or C/EBPbeta oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF-kappaB p50 bound to the bcl-2 and FLIP gene promoters.** *Leukemia* 2009, **23**:365–374.
24. Pise-Masison CA, Dittmer J, Clemens KE, Brady JN: **Physical and functional interaction between the human T-cell lymphotropic virus type 1 Tax1 protein and the CCAAT binding protein NF-Y.** *Mol Cell Biol* 1997, **17**:1236–1243.
25. Hivin P, Gaudray G, Devaux C, Mesnard JM: **Interaction between C/EBPbeta and Tax down-regulates human T-cell leukemia virus type I transcription.** *Virology* 2004, **318**:556–565.
26. Tsukada J, Misago M, Serino Y, Ogawa R, Murakami S, Nakanishi M, Tonai S, Kominato Y, Morimoto I, Auron PE, Eto S: **Human T-cell leukemia virus type I Tax transactivates the promoter of human prointerleukin-1beta gene through association with two transcription factors, nuclear factor-interleukin-6 and Spi-1.** *Blood* 1997, **90**:3142–3153.
27. Pise-Masison CA, Radonovich M, Dohoney K, Morris JC, O'Mahony D, Lee MJ, Trepel J, Waldmann TA, Janik JE, Brady JN: **Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRCS gene expression and cell viability.** *Blood* 2009, **113**:4016–4026.
28. Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A, Matsuda Y, Sato-Otsubo A, Muto S, Utsunomiya A, et al: **Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers.** *Cancer Cell* 2012, **21**:121–135.
29. Grant C, Nonnemacher M, Jain P, Pandya D, Irish B, Williams SC, Wigdahl B: **CCAAT/enhancer-binding proteins modulate human T cell leukemia virus type 1 long terminal repeat activation.** *Virology* 2006, **348**:354–369.
30. Hagiya K, Yasunaga J, Satou Y, Ohshima K, Matsuoka M: **ATF3, an HTLV-1 bZip factor binding protein, promotes proliferation of adult T-cell leukemia cells.** *Retrovirology* 2011, **8**:19.
31. Satou Y, Yasunaga J, Zhao T, Yoshida M, Miyazato P, Takai K, Shimizu K, Ohshima K, Green PL, Ohkura N, et al: **HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo.** *PLoS Pathogens* 2011, **7**:e1001274.
32. Choy L, Derynck R: **Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function.** *J Biol Chem* 2003, **278**:9609–9619.
33. Nerlov C: **C/EBPs: recipients of extracellular signals through proteome modulation.** *Curr Opin Cell Biol* 2008, **20**:180–185.
34. Fan J, Ma G, Nosaka K, Tanabe J, Satou Y, Koito A, Wain-Hobson S, Vartanian JP, Matsuoka M: **APobec3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo.** *J Virol* 2010, **84**:7278–7287.
35. Matsuoka M: **Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL).** *Retrovirology* 2005, **2**:27.
36. Yoshida M: **Multiple viral strategies of HTLV-1 for dysregulation of cell growth control.** *Annu Rev Immunol* 2001, **19**:475–496.
37. Mulloy JC, Kislyakova T, Cereseto A, Casareto L, LoMonico A, Fullen J, Lorenzi MV, Cara A, Nicot C, Giam C, Franchini G: **Human T-cell lymphotropic/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB/ATF functional domain.** *J Virol* 1998, **72**:8852–8860.
38. Kannagi M, Harada S, Maruyama I, Inoko H, Igarashi H, Kuwashima G, Sato S, Morita M, Kidokoro M, Sugimoto M, et al: **Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells.** *Int Immunol* 1991, **3**:761–767.

39. Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Muller-Tidow C, Bohlander SK, Tenen DG, Behre G: **Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia.** *Blood* 2010, **115**:1768–1778.
40. Lu GD, Leung CH, Yan B, Tan CM, Low SY, Aung MO, Salto-Tellez M, Lim SG, Hooi SC: **C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation.** *Gastroenterology* 2010, **139**:632–643. 643 e631–634.
41. White JD, Zaknoen SL, Kasten-Sportes C, Top LE, Navarro-Roman L, Nelson DL, Waldmann TA: **Infectious complications and immunodeficiency in patients with human T-cell lymphotropic virus I-associated adult T-cell leukemia/lymphoma.** *Cancer* 1995, **75**:1598–1607.
42. Nicot C: **Current views in HTLV-I-associated adult T-cell leukemia/lymphoma.** *Am J Hematol* 2005, **78**:232–239.
43. Sugata K, Satou Y, Yasunaga J, Hara H, Ohshima K, Utsunomiya A, Mitsuyama M, Matsuoka M: **HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines.** *Blood* 2012, **119**:434–444.
44. Shimatani K, Nakashima Y, Hattori M, Hamazaki Y, Minato N: **PD-1+ memory phenotype CD4+ T cells expressing C/EBPalpha underlie T cell immunodepression in senescence and leukemia.** *Proc Natl Acad Sci USA* 2009, **106**:15807–15812.
45. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Biccato S, Falisi E, et al: **Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.** *Immunity* 2010, **32**:790–802.
46. Choi BH, Park GT, Rho HM: **Interaction of hepatitis B viral X protein and CCAAT/enhancer-binding protein alpha synergistically activates the hepatitis B viral enhancer II/pregenomic promoter.** *J Biol Chem* 1999, **274**:2858–2865.
47. Bristol JA, Robinson AR, Barlow EA, Kenney SC: **The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins.** *J Virol* 2010, **84**:12362–12374.
48. Liu Y, Nonnemacher MR, Wigdahl B: **CCAAT/enhancer-binding proteins and the pathogenesis of retrovirus infection.** *Future Microbiol* 2009, **4**:299–321.
49. Wang SE, Wu FY, Yu Y, Hayward GS: **CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi's sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters.** *J Virol* 2003, **77**:9590–9612.
50. Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T, Takaku H, Shimotohno K: **HCV infection induces inflammatory cytokines and chemokines mediated by the cross-talk between hepatocytes and stellate cells.** *J Virol* 2013, **87**:8169–8178.
51. Fields J, Gardner-Mercer J, Borgmann K, Clark I, Ghorpade A: **CCAAT/enhancer binding protein beta expression is increased in the brain during HIV-1-infection and contributes to regulation of astrocyte tissue inhibitor of metalloproteinase-1.** *J Neurochem* 2011, **118**:93–104.
52. Zhi HJ, Yang LP, Kuo YL, Ho YK, Shih HM, Giam CZ: **NF-kappa B Hyper-activation by HTLV-1 tax induces cellular senescence, but can be alleviated by the viral anti-sense protein HBZ.** *PLoS Pathogens* 2011, **7**:e1002025.
53. Kuhlmann AS, Villaudy J, Gazzolo L, Castellazzi M, Duc Dodon M: **HTLV-1 HBZ cooperates with JunD to enhance transcription of the human telomerase reverse transcriptase gene (hTERT).** *Retrovirology* 2007, **4**:92.
54. Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J: **C/EBPbeta at the core of the TGFbeta cytosstatic response and its evasion in metastatic breast cancer cells.** *Cancer Cell* 2006, **10**:203–214.
55. Yamamoto-Taguchi N, Satou Y, Miyazato P, Ohshima K, Nakagawa M, Katagiri K, Kinashi T, Matsuoka M: **HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression.** *PLoS Pathog* 2013, **9**:e1003630.
56. Jazag A, Kanai F, Ijichi H, Tateishi K, Ikenoue T, Tanaka Y, Ohta M, Imamura J, Guleng B, Asaoka Y, et al: **Single small-interfering RNA expression vector for silencing multiple transforming growth factor-beta pathway components.** *Nucleic Acids Res* 2005, **33**:e131.
57. Morita S, Kojima T, Kitamura T: **Plat-E: an efficient and stable system for transient packaging of retroviruses.** *Gene Ther* 2000, **7**:1063–1066.

doi:10.1186/1742-4690-10-159

Cite this article as: Zhao et al.: HTLV-1 bZIP factor supports proliferation of adult T cell leukemia cells through suppression of C/EBPalpha signaling. *Retrovirology* 2013 **10**:159.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

